Achieve Life Sciences received an FDA Complete Response Letter for its cytisinicline New Drug Application citing only third-party manufacturing deficiencies, with the agency identifying no efficacy or clinical safety concerns, providing a clear regulatory pathway toward a first-half 2027 approval.

Key Highlights

  • The FDA's CRL identified zero clinical efficacy or safety deficiencies for cytisinicline, with the only issues relating to manufacturing observations at a prior third-party facility already replaced by Adare Pharma Solutions.
  • Achieve completed analytical method technology transfer to Adare, successfully manufactured its first engineering batch, and fully qualified all testing procedures, with NDA resubmission targeted for Q4 2026.
  • Shares rose roughly 7.6% to $5.22 on the session as markets registered relief that the drug's Phase 3 clinical foundation remains fully intact.

Achieve Life Sciences, Inc. (NASDAQ: ACHV) announced Monday that it has received a Complete Response Letter from the FDA regarding the cytisinicline New Drug Application for smoking cessation. Shares rose roughly 7.6% to $5.22, reflecting market relief that the FDA's feedback was confined entirely to manufacturing-related observations at a prior third-party facility, with no deficiencies identified regarding clinical efficacy or safety.

The outcome was anticipated. As the company disclosed on April 15, 2026, it expected to receive a CRL on or before its June 20 PDUFA date, and had pre-emptively partnered with Adare Pharma Solutions as its new primary commercial partner. Achieve has completed analytical method technology transfer, successfully manufactured its first cytisinicline engineering batch, and fully qualified all testing procedures at the Adare facility.

The cytisinicline NDA is supported by more than 1,500 clinical trial participants. In the pivotal ORCA-2 and ORCA-3 trials, cytisinicline administered for six or twelve weeks alongside standard behavioural support demonstrated significantly greater smoking abstinence rates at end of treatment and through week 24 compared to placebo. Beyond smoking cessation, cytisinicline holds FDA Breakthrough Therapy designation for nicotine e-cigarette cessation, an indication with no currently approved treatments despite nearly 18 million adult US e-cigarette users.